glp-1 agonist alcohol IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target Ozempic and Other GLP-1 Drugs
Description
doi: 10.1016/j.bbr.2015.07.024
L., Tabesh, M., Koye, D
The Med+ membership is required and is an additional cost (check WeightWatchers website for current membership pricing)
Clinical trials show average weight loss of 14.9% over 68 weeks
This breakthrough treatment helps regulate blood sugar, suppress appetite, and support long-term weight management
